First-in-class bispecific antibody, alg.apv-527, meets important trial endpoints in phase 1 solid tumor trial

Aptevo therapeutics and alligator bioscience report favorable safety, tolerability and evidence of biological activity of alg.apv-527, more than half of evaluable patients achieved stable disease colon cancer patient achieved stable disease and remained on study for more than six months, breast cancer patient remained on study for more than 11 months biomarker analysis confirms immune activation in the tumor microenvironment data presented at society for immunotherapy of cancer on november 8, 2024 seattle, wa and lund, sweden / accesswire / november 11, 2024 / aptevo therapeutics ("aptevo") (nasdaq:apvo) and alligator bioscience ab ("alligator") (atorx) today announced preliminary data from the companies' phase 1 trial evaluating the first-in-class bispecific antibody, alg.apv-527, as monotherapy for the treatment of multiple solid tumor types likely to express tumor antigen 5t4. these data indicate that trial endpoints of adequate exposure, safety, tolerability and biological activity were met.
ALG Ratings Summary
ALG Quant Ranking